Wednesday June 28, 2023 | 8am PDT, 11am EDT, 4pm BST

Planning for access in some EU markets is often left until after an asset is reimbursed in the EU5 markets. 

As a member of the PRMA Navigator® team, Claire leads delivery of PRMA Navigator® projects. She has more than 15 years’ experience in market access, with a particular interest in defining evidence generation strategies and developing value demonstration materials, including payer marketing materials, product value dossiers, HTA submissions, and HEOR publications. Claire has provided strategic and editorial support across a number of therapeutic areas, including oncology, arthropathies, infection, diabetes, and neuroscience. She holds a PhD in Cancer Studies from the University of Manchester.

Vanya has more than 5 years’ experience in market access consultancy. At PRMA Consulting, she has worked across a range of different projects, including strategic landscape assessments using the PRMA Healthcheck^® digital application to develop evidence generation roadmaps for market access, primary research with payers and KOLs, research on the role of real-world evidence in HTA, and drafting HTA submissions using the PRMA Navigator^® application. Vanya has expertise across a range of therapeutic areas including oncology, cardiovascular, and metabolic disorders, and rare disease. Vanya holds a PhD from King’s College London and an MSc from Imperial College London.

Jonathan has several years’ experience in market access consulting and has been involved in a broad range of projects at PRMA Consulting. He is a member of the PRMA Navigator^® team and has helped generate partial HTA submissions for a number of European markets across a range of indications. He is also a content manager for the PRMA Navigator^®, responsible for adapting submission templates from major HTA agencies for use with the PRMA Navigator^®. Other project experiences have included work on developing global value materials, evidence generation planning, and situation analyses. Jonathan is the author of several publications in leading neuroscience and behavioral pharmacology journals. He has a PhD in Behavioral Pharmacology from the University of Cambridge.

Adriana Dacheva holds a PhD in Social Medicine and Health Management. In 2017, she completed her postgraduate qualification in Health Management. Adriana Dacheva has 7 years of experience working on HTA dossier preparation and more specifically as a budget impact analyst. Specializes additionally in Glasgow, Barcelona, Copenhagen, Milan, Washington, Vienna, and taking part in courses organized by ISPOR in the field of HTA and, in particular, in budgetary impact area, risk-sharing agreements. Since the beginning of 2020, she has been actively involved in projects related to value-based healthcare (VBHC) in Bulgaria. She is teaching HTA and VBHC at medical universities and business schools (MU Pleven, AUBG, Charles University Prague,) and is a co-author of books, articles on HTA, VBHC.

Dr Slaveyko Djambazov has international expertise as a consultant on health policy, HTA, VBHC. He is a medical doctor, holding a PhD in HTA, an MBA from the American University in Bulgaria (AUBG), and a master’s degree in public health. Dr Djambazov also completed an executive course at Harvard Business School for VBHC with Prof Porter and Prof Kaplan. He is teaching HTA and VBHC at medical universities and business schools (MU Pleven, AUBG, Charles University Prague, St Andrews Scotland) and is a co-author of books on HTA, health economics, clinical trials, VBHC, >100 research papers. Dr Djambazov is the founder and managing director of HTA Ltd. For the last 8 years, HTA Ltd. has prepared >800 analyses for >80 multinational companies. Since 2017, Dr Djambazov has been actively working with investment groups, governments, and royal families on large investment projects in Africa and Central/Southeast Asia.

Duration: 30 minutes.

Broadcast: 2023